University of California, Irvine School of Medicine

Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Disney Channel Hits: Take 2, Lilly, Eli Lilly and Company, Boehringer Ingelheim, Dean (education), NYSE, EGFR, UC, Human, Kidney, LLY, Diabetes, Inclusion, Glomerular filtration rate, HIV disease progression rates, UACR, FAAFP, Chronic kidney disease, Risk, University of California, Irvine School of Medicine, Kidney disease, Blood, Diversity, CKD, It Takes Two, Patient, Diagnosis, Heart failure, Head, Pharmaceutical industry, Nursing, Medicine, F.A.C.E

More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.

Key Points: 
  • More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.
  • By turning "It Takes Two" into "It Takes 2 – The Remix," he is helping Boehringer Ingelheim and Lilly reach key audiences to spotlight the significance of complete testing.
  • It Takes 2 encourages healthcare professionals to add UACR testing to screen for CKD, as eGFR testing only tells half the story.
  • By tapping into a powerful combination of nostalgia and memorability, It Takes 2 is helping bring greater recognition to kidney disease."

Breast Expert Dr. Josh Waltzman Joins Exclusive Haute Beauty Network

Retrieved on: 
Monday, October 30, 2023
Plastic, Beauty, University, Face, Plastic surgery, Research, Plastic and Reconstructive Surgery, University of California, Irvine School of Medicine, Paul Merage School of Business, Business, Cleveland Clinic, Patient, Breast, Happiness, Dentistry, Medicine

NEW YORK, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Dr. Josh Waltzman is a Board Certified Plastic Surgeon who believes every patient deserves high-quality, safe, and individualized care to help optimize their own personal goals. With his years of training in Plastic and Reconstructive Surgery and a rooted passion for the field, Dr. Waltzman is dedicated to helping achieve the objectives of his patients with regard for what is aesthetically natural and functional.

Key Points: 
  • Dr. Josh Waltzman joins Haute Beauty Network as a breast expert representing the Los Angeles market.
  • NEW YORK, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Dr. Josh Waltzman is a Board Certified Plastic Surgeon who believes every patient deserves high-quality, safe, and individualized care to help optimize their own personal goals.
  • After graduating magna cum laude from the University of Southern California, Dr. Waltzman attended the University of California Irvine School of Medicine.
  • Dr. Waltzman has been invited to present his research to other Plastic Surgeons at numerous national and international meetings.

Hoag Welcomes Dr. Ronald Wolf as Medical Director of Hepatobiliary and Pancreatic Surgery

Retrieved on: 
Tuesday, October 17, 2023
Colon, University of California, Davis, American College, Agility, Cancer, UC, Medical director, Oregon Health & Science University, Pancreas, Memorial Sloan Kettering Cancer Center, Surgical oncology, University of California, Irvine School of Medicine, Culture, General surgery, Society, Patient, Legacy Good Samaritan Medical Center, Medical imaging, Nursing, Dentistry, Liver, Medicine

NEWPORT BEACH, Calif. and IRVINE, Calif., Oct. 17, 2023 /PRNewswire/ -- Hoag is proud to announce the recruitment of Ronald Wolf, M.D., F.A.C.S., as medical director of hepatobiliary and pancreas surgery at Hoag Family Cancer Institute.

Key Points: 
  • NEWPORT BEACH, Calif. and IRVINE, Calif., Oct. 17, 2023 /PRNewswire/ -- Hoag is proud to announce the recruitment of Ronald Wolf, M.D., F.A.C.S., as medical director of hepatobiliary and pancreas surgery at Hoag Family Cancer Institute.
  • Dr. Wolf comes to Hoag from concurrent posts at UC Irvine School of Medicine, where he served as professor of clinical surgery in the hepatobiliary and pancreas surgery/islet cell transplantation division.
  • Prior to that, he served as Medical Director of Hepatic and Pancreatic Surgery at Legacy Good Samaritan Medical Center in Portland, Oregon, and as the Medical Director of Liver and Pancreas Surgery at Providence Cancer Center, also in Portland.
  • Dr. Wolf received his medical degree from Oregon Health & Science University in Portland, followed by an internship and two residencies in general surgery at UC Davis.

CORRECTION: Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 11, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, University, CDC, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Nursing home, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

The findings were published on October 10, 2023, in the New England Journal of Medicine.

Key Points: 
  • The findings were published on October 10, 2023, in the New England Journal of Medicine.
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • “Nursing Home Decolonization for Infection and Hospitalization Prevention” published in the New England Journal of Medicine on October 10, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2215254?query=featured_home

Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New English Journal of Medicine

Retrieved on: 
Tuesday, October 10, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, CDC, University, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

“The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.

Key Points: 
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • Each year, 3 million healthcare-associated infections (HAIs) such as methicillin-resistant Staphylococcus aureus (MRSA), bloodstream and urinary tract infections occur in U.S. nursing homes.
  • The findings add to a growing body of Dr. Miller’s research that has been funded by NIH, AHRQ, and other federal sources.

Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations

Retrieved on: 
Monday, October 9, 2023
Titan, Nanomedicine, Ophthalmology, ALS, Neuroscience, Senior, Ashvattha, University of California, Irvine School of Medicine, University of Colorado Boulder Computer Science Department, Amgen, Research, Neuro, DME, Inflammation, Therapy, Neurology, IND, Titan Pharmaceuticals, CV, Grifols, AMD, University, Georgetown University, Laboratory, Microglia, Head, Macrophage, Pfizer, System, StemCells, Inc., Translational medicine, Patient, Pharmaceutical industry, Recode

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.
  • Ms. Thayer has more than 20 years of progressive leadership experience in clinical development operations across various therapeutic areas from Phase 1 through Phase 3.
  • She previously served as Vice President, Head of Clinical Operations at Recode Therapeutics where she established the clinical operations function at the company.
  • Prior to Recode, she led clinical operations at Global Blood Therapeutics (Pfizer), StemCells Inc, FivePrime Therapeutics (Amgen), CV Therapeutics (Gilead), Titan Pharmaceuticals and Becton Dickinson Immunocytometry Systems.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Board-certified Dermatologist Dr. Blair Rose Announces the Launch of Skincare Junkie

Retrieved on: 
Tuesday, October 3, 2023
Weill Cornell Medical Center, Rosacea, Montefiore Medical Center, University, Shareasale, Helsinki University Central Hospital, Business Insider, Salicylic acid, Cowra breakout, Dermatitis, University of California, Irvine School of Medicine, Antioxidant, Merchant, Skin cancer, Pediatric Dermatology, Vogue, Skin, Phthalate, Women's health, American Academy, Hyaluronic acid, Acne, Multimedia, FAAD, Pore, Psoriasis, John Foster Dulles, Journal, PHA, Publication, PRP, Patient, Irritation, Confusion, Albert Einstein College of Medicine, Ceramide, Cosmetics, Dermatology, Elle, MD, Medicine

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.
  • Dr. Rose created Skincare Junkie out of necessity when she noticed countless patients developing breakouts and skin irritation from popular skincare products.
  • "I needed to create a line of non-toxic, hypoallergenic skincare that I would feel confident suggesting to my patients and that they would enjoy using" says Dr. Rose.
  • Blair Murphy Rose, MD, FAAD , is an award-winning board-certified dermatologist seeing patients in NYC and a clinical instructor of dermatology at the Weill Cornell Medical Center.

Angeles Equity Partners Adds Steve Tamjidi to Business Development Team

Retrieved on: 
Wednesday, September 13, 2023
Consulting, Professional Services, Finance, Phoenix Equity Partners, Regent, L.P., Business development, University, University of California, Irvine School of Medicine, Partner, Financial services, Hamid Tamjidi, Anthropology

Angeles Equity Partners, LLC (“Angeles”), a private investment firm focused on value creation through operational transformation, has appointed Steve Tamjidi to its business development team.

Key Points: 
  • Angeles Equity Partners, LLC (“Angeles”), a private investment firm focused on value creation through operational transformation, has appointed Steve Tamjidi to its business development team.
  • These relationships, combined with his strategic and analytical approach to business development, make him an exceptional addition to our team,” said Max Schechter, principal and head of Business Development for Angeles Equity Partners.
  • Prior to joining Angeles, Tamjidi led business development at Architect Equity Partners, where he sourced and qualified new investment opportunities.
  • Prior to his experience at Architect Equity, Tamjidi worked in business development at Ascension Equity Partners and Regent Equity Partners.

Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer

Retrieved on: 
Wednesday, August 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Micrometer (device), Industrial engineering, Teva Pharmaceuticals, KRAS, Partnership, University, Therapy, University of California, Irvine School of Medicine, Bi-specific T-cell engager, Bachelor of Technology, Cancer, MBA, Protein Sciences, Acquisition, Motilal Nehru National Institute of Technology Allahabad, Carnegie Mellon University, Catena, Growth, Merck, Commercial, Kite Pharma, Imagination, Saurabh, PARP, Management, Fine chemical, Amgen, Bayer, Chemistry, Medicine

Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.

Key Points: 
  • Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.
  • The company has appointed Saurabh Johri as Chief Business Officer and Rick Kendall, Ph.D., as Chief Scientific Officer.
  • “Catena is in an exciting phase of growth, and we are pleased to welcome Saurabh and Rick to our growing team.
  • Saurabh joins Catena Biosciences from Bayer where he was most recently Vice President & Global Head, Oncology Strategy and Early Commercialization.